SI-BONE to Present at the 2021 JMP Securities Life Sciences Conference

SANTA CLARA, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN) announced its participation in the 2021 JMP Securities Life Sciences Conference.

Rhea-AI Summary

SANTA CLARA, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN) announced its participation in the 2021 JMP Securities Life Sciences Conference. The company is set to present on June 17 at 2:30 p.m. ET. Interested parties can access a live and archived webcast on the company’s website. SI-BONE specializes in minimally invasive surgery of the SI joint with its iFuse Implant System, which has demonstrated effectiveness for treating chronic low back pain associated with sacroiliac joint dysfunction.

Argus Session date unavailable

-1.54% session move Open Argus

Details

News Market Reaction – SIBN

The recorded move for SIBN in the trading session of this news was -1.54%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SANTA CLARA, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2021 JMP Securities Life Sciences Conference. Management is scheduled to present on Thursday, June 17 at 2:30 p.m. Eastern Time / 11:30 a.m. Pacific Time.

Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: www.si-bone.com

About SI-BONE, Inc.
SI-BONE is a medical device company that pioneered minimally invasive surgery of the SI joint with the iFuse Implant System. Studies have shown that the SI joint can be a source of pain in 15% to 30% of chronic low back pain. The iFuse Implant™, commercially available since 2009, is the only SI joint fusion device supported by multiple prospective clinical studies, including two randomized controlled trials, showing improved pain, patient function and quality of life resulting from treatment. There are over 90 peer-reviewed publications demonstrating the safety, durable effectiveness, and biomechanical and economic benefits unique to the iFuse Implant (www.si-bone.com/results). This body of evidence has enabled multiple government and private insurance payors to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System.

The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. The iFuse Implant System is also intended for sacroiliac fusion to augment stabilization and immobilization of the sacroiliac joint in skeletally mature patients undergoing sacropelvic fixation as part of a lumbar or thoracolumbar fusion. In addition, the iFuse Implant System is intended for sacroiliac fusion in acute, non-acute, and non-traumatic fractures involving the sacroiliac joint. There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit.

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2021 SI-BONE, Inc. All Rights Reserved. 06082021

Investor Contact:
Matt Bacso, CFA
investors@SI-BONE.com

Media Contact:
Joe Powers
jpowers@si-bone.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is SI-BONE's presentation at the 2021 JMP Securities Life Sciences Conference?

SI-BONE will present on June 17, 2021, at 2:30 p.m. Eastern Time.

How can I access SI-BONE's conference presentation?

You can access a live and archived webcast of the presentation on the Investors section of SI-BONE's website.

What is the focus of SI-BONE's iFuse Implant System?

The iFuse Implant System focuses on solving musculoskeletal disorders of the sacropelvic anatomy, particularly sacroiliac joint dysfunction.

What is the significance of the iFuse Implant in treating chronic low back pain?

Studies indicate that the iFuse Implant is effective in treating chronic low back pain caused by sacroiliac joint issues, supported by multiple clinical studies.